REFERENCES
- Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71 (3): 587–91.
- Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8 (2): 163–8.
- Glimelius B, Hoffman K, Haglund U, Nyren 0, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5 (2): 189–90.
- Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80(1-2): 269–72.
- Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15 (3): 921–7.
- Saltz LB, Spriggs D, Schaaf II, et al. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 1998; 16 (12): 3858–65.
- Glimelius B, Hoffman K, Graf W, et al. Cost-effective-ness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6 (3): 267–74.
- Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gas-tric cancer. J Clin Oncol 1999; 17 (1): 319–23.
- Yoshida M, Boku N, Ohtsu A, Muto M, Nagashima F, Yoshida S. Combination chemotherapy of irinotecan plus cis-platin for advanced gastric cancer: efficacy and feasibility in clinical practice. Gastric Cancer 2001; 4 (3): 144–9.
- Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cis-platin in patients with advanced, untreated gastric or gastroe-sophageal junction carcinoma: results of a phase II study. Cancer 2002; 94 (3): 641–6.
- Yamao T, Kai S, Kazami A, et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to sys-temic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999; 29 (11): 550–5.
- O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998; 34 (10): 1500–8.
- Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20 (1): 81–7.
- Rivory LP. Metabolism of CPT-11. Impact on activity. Ann N Y Acad Sci 2000; 922: 205–15.
- Armand JP, Terret C, Couteau C, Rixe O. CPT-11. The European experience. Ann NY Acad Sci 1996; 803: 282–91.
- Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7 (8): 2182–94.
- Balram C, Sabapathy K, Fei G, Khoo KS, Lee EJ. Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 2002; 12 (1): 81–3.
- Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54 (14): 3723–5.
- Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymor-phism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2 (1): 43–7.
- Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002; 24 (1): 111–6.
- Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60 (24): 6921–6.
- Sato A, Kurihara M, Matsukawa M, et al. Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin ther-apy in patients with advanced gastric and colorectal cancer. Cancer Chemother Pharmacol 2001; 47 (5): 380–4.